OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Feb 05, 2022;23 (3):

The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.

Thomas Kubin, Praveen Gajawada, Peter Bramlage, Stefan Hein, Benedikt Berge, Ayse Cetinkaya, Heiko Burger, Markus Schönburg, Wolfgang Schaper, Yeong-Hoon Choi, Manfred Richter
Author Information
  1. Thomas Kubin: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  2. Praveen Gajawada: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  3. Peter Bramlage: Institute for Pharmacology and Preventive Medicine GmbH, Bahnhofstraße 20, 49661 Cloppenburg, Germany.
  4. Stefan Hein: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  5. Benedikt Berge: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  6. Ayse Cetinkaya: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  7. Heiko Burger: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany. ORCID
  8. Markus Schönburg: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  9. Wolfgang Schaper: Max-Planck-Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany.
  10. Yeong-Hoon Choi: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
  11. Manfred Richter: Department of Cardiac Surgery, Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany. ORCID
PMID: 35163735 DOI: 10.3390/ijms23031811

Abstract

Oncostatin M (OSM), a member of the interleukin-6 family, functions as a major mediator of cardiomyocyte remodeling under pathological conditions. Its involvement in a variety of human cardiac diseases such as aortic stenosis, myocardial infarction, myocarditis, cardiac sarcoidosis, and various cardiomyopathies make the OSM receptor (OSMR) signaling cascades a promising therapeutic target. However, the development of pharmacological treatment strategies is highly challenging for many reasons. In mouse models of heart disease, OSM elicits opposing effects via activation of the type II receptor complex (OSMR/gp130). Short-term activation of OSMR/gp130 protects the heart after acute injury, whereas chronic activation promotes the development of heart failure. Furthermore, OSM has the ability to integrate signals from unrelated receptors that enhance fetal remodeling (dedifferentiation) of adult cardiomyocytes. Because OSM strongly stimulates the production and secretion of extracellular proteins, it is likely to exert systemic effects, which in turn, could influence cardiac remodeling. Compared with the mouse, the complexity of OSM signaling is even greater in humans because this cytokine also activates the type I leukemia inhibitory factor receptor complex (LIFR/gp130). In this article, we provide an overview of OSM-induced cardiomyocyte remodeling and discuss the consequences of OSMR/gp130 and LIFR/gp130 activation under acute and chronic conditions.

Keywords

cardiomyocyte dedifferentiation gp130 heart failure inflammation interleukin-6 leukemia inhibitory factor receptor myocardial infarction oncostatin M receptor remodeling

References

Curr Heart Fail Rep. 2015 Feb;12(1):33-41 [PMID: 25315037]
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H183-9 [PMID: 27199120]
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):407-11 [PMID: 8552649]
Peptides. 2019 Jan;111:18-25 [PMID: 29859763]
J Biol Chem. 1998 Apr 17;273(16):9703-10 [PMID: 9545305]
EMBO J. 1991 Oct;10(10):2839-48 [PMID: 1915266]
Atherosclerosis. 2011 Jun;216(2):292-8 [PMID: 21376322]
FASEB J. 2003 Nov;17(14):2118-20 [PMID: 12958147]
Blood. 1993 Jun 15;81(12):3226-33 [PMID: 7685199]
PLoS One. 2019 Aug 28;14(8):e0221477 [PMID: 31461490]
Stem Cell Rev Rep. 2012 Mar;8(1):1-15 [PMID: 21537995]
Cell Tissue Res. 2005 Jul;321(1):57-66 [PMID: 15902494]
Nature. 2009 Jul 2;460(7251):118-22 [PMID: 19571885]
Circulation. 2003 Feb 18;107(6):798-802 [PMID: 12591746]
J Mol Cell Cardiol. 2021 Mar;152:80-91 [PMID: 33275936]
Biomed Res Int. 2015;2015:317905 [PMID: 26146616]
EMBO J. 1996 Mar 1;15(5):1055-63 [PMID: 8605875]
Dis Markers. 2020 Jul 22;2020:9356738 [PMID: 32774516]
Circulation. 2001 Mar 6;103(9):1296-302 [PMID: 11238276]
Res Commun Mol Pathol Pharmacol. 1997 Jul;97(1):3-12 [PMID: 9507563]
J Mol Cell Cardiol. 2011 Feb;50(2):280-9 [PMID: 20727900]
Sci Rep. 2020 Nov 25;10(1):20533 [PMID: 33239683]
Cytokine. 2020 Mar 20;130:155053 [PMID: 32203694]
Eur J Heart Fail. 2003 Mar;5(2):137-45 [PMID: 12644003]
EMBO J. 2001 Oct 1;20(19):5431-42 [PMID: 11574475]
J Mol Cell Cardiol. 1996 Jan;28(1):19-31 [PMID: 8745211]
Nature. 1992 Oct 22;359(6397):693-9 [PMID: 1436033]
Nat Rev Immunol. 2018 Dec;18(12):773-789 [PMID: 30254251]
Circulation. 1997 Apr 1;95(7):1961-71 [PMID: 9107186]
J Heart Lung Transplant. 2007 Nov;26(11):1170-6 [PMID: 18022084]
Nature. 1992 Sep 3;359(6390):76-9 [PMID: 1522892]
Circ Res. 2015 Mar 27;116(7):1254-68 [PMID: 25814686]
Circ Res. 1999 Dec 3-17;85(12):1124-31 [PMID: 10590238]
Eur Heart J. 2010 Apr;31(7):784-93 [PMID: 20207624]
Proc Natl Acad Sci U S A. 1995 May 23;92(11):4862-6 [PMID: 7539136]
Int J Mol Sci. 2021 Apr 16;22(8): [PMID: 33923774]
J Immunol. 2006 Dec 15;177(12):8740-7 [PMID: 17142776]
Cell Stem Cell. 2011 Nov 4;9(5):420-32 [PMID: 22056139]
Front Immunol. 2014 Sep 23;5:456 [PMID: 25295040]
Front Cardiovasc Med. 2019 Sep 18;6:140 [PMID: 31620450]
J Exp Med. 2020 May 4;217(5): [PMID: 32267936]
Circ Res. 2013 Aug 30;113(6):646-59 [PMID: 23989710]
Mol Cell Biochem. 1998 Sep;186(1-2):159-68 [PMID: 9774197]
Biomed Res Int. 2015;2015:212910 [PMID: 26236717]
Front Cell Dev Biol. 2021 Oct 28;9:745892 [PMID: 34778257]
Am J Physiol. 1999 Jun;276(6):H2179-87 [PMID: 10362702]
Int J Cardiol. 1997 Aug 8;60(3):273-9 [PMID: 9261638]
Genomics. 1993 Jul;17(1):136-40 [PMID: 8406444]
Adv Exp Med Biol. 2001;495:145-51 [PMID: 11774558]
ASAIO J. 2021 Nov 17;: [PMID: 34772849]
Clin Res Cardiol. 2019 Jun;108(6):612-621 [PMID: 30367209]
J Card Fail. 1996 Sep;2(3):243-9 [PMID: 8891862]
J Mol Cell Cardiol. 1995 Jan;27(1):223-9 [PMID: 7760346]
J Mol Med (Berl). 1997 Nov-Dec;75(11-12):901-20 [PMID: 9428623]
Eur J Heart Fail. 2001 Aug;3(4):415-21 [PMID: 11511426]
Cytokine. 2015 Jul;74(1):62-8 [PMID: 25649043]
J Biol Chem. 2018 Dec 28;293(52):20181-20199 [PMID: 30373773]
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H277-84 [PMID: 15778284]
Trends Cardiovasc Med. 2003 Jan;13(1):30-8 [PMID: 12554098]
J Neuropathol Exp Neurol. 2001 Nov;60(11):1087-98 [PMID: 11706938]
Circulation. 2010 Jul 13;122(2):145-55 [PMID: 20585009]
Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):823-7 [PMID: 8430092]
Sci Adv. 2021 Oct 15;7(42):eabi6648 [PMID: 34644107]
Nat Neurosci. 2016 Jun;19(6):798-806 [PMID: 27110918]
Am J Physiol Renal Physiol. 2009 Apr;296(4):F875-83 [PMID: 19158344]
Front Immunol. 2017 Feb 09;8:131 [PMID: 28232838]
Mol Cell Biochem. 2003 Jan;242(1-2):47-55 [PMID: 12619865]
Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1835-42 [PMID: 10446061]
J Mol Cell Cardiol. 2005 Sep;39(3):545-51 [PMID: 15890357]
Exp Clin Cardiol. 2009 Fall;14(3):e68-75 [PMID: 20098571]
Cell Physiol Biochem. 2008;21(4):305-14 [PMID: 18441519]
Basic Res Cardiol. 2014 Jan;109(1):396 [PMID: 24292852]
J Biol Chem. 2018 May 4;293(18):7017-7029 [PMID: 29511087]
Cardiovasc Res. 2003 Sep 1;59(3):628-38 [PMID: 14499864]
Lab Invest. 2001 Feb;81(2):133-41 [PMID: 11232634]
J Immunol. 2016 Jul 1;197(1):11-8 [PMID: 27317733]
Cytokine Growth Factor Rev. 2015 Oct;26(5):533-44 [PMID: 26187859]
Circulation. 2003 Jul 1;107(25):3133-40 [PMID: 12796126]
Circulation. 1999 Feb 2;99(4):546-51 [PMID: 9927402]
Eur J Heart Fail. 2019 Aug;21(8):965-973 [PMID: 31087601]
Stem Cells. 2007 Jan;25(1):236-44 [PMID: 16973829]
Nat Rev Drug Discov. 2012 Aug;11(8):633-52 [PMID: 22850787]
Ann N Y Acad Sci. 1995 Jul 21;762:407-9 [PMID: 7668543]
J Cell Mol Med. 2009 May;13(5):896-908 [PMID: 19538254]
Croat Med J. 2004 Apr;45(2):149-57 [PMID: 15103750]
J Thorac Cardiovasc Surg. 2004 Dec;128(6):866-75 [PMID: 15573071]
Cardiovasc Res. 2003 Feb;57(2):523-34 [PMID: 12566125]
Am J Transl Res. 2021 Oct 15;13(10):11329-11340 [PMID: 34786061]
J Am Coll Cardiol. 1996 Jun;27(7):1577-85 [PMID: 8636539]
EMBO J. 1987 Dec 20;6(13):3995-4002 [PMID: 3127201]
Basic Res Cardiol. 2007 Jul;102(4):279-97 [PMID: 17530315]
Int J Mol Sci. 2020 Sep 01;21(17): [PMID: 32882982]
Gen Comp Endocrinol. 2018 Feb 1;257:143-160 [PMID: 28652136]
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4 [PMID: 8421714]
Oncotarget. 2019 Mar 12;10(21):2068-2085 [PMID: 31007849]
Blood. 1993 Jul 1;82(1):33-7 [PMID: 7686788]
Front Immunol. 2020 Jul 16;11:1424 [PMID: 32765502]
EMBO Rep. 2018 Dec;19(12): [PMID: 30337494]
Cell Mol Life Sci. 2014 May;71(10):1907-16 [PMID: 24322910]
Eur Heart J. 2002 Jun;23(11):849-57 [PMID: 12042006]
J Heart Lung Transplant. 2015 Sep;34(9):1211-4 [PMID: 26267742]
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):347-56 [PMID: 18926762]
J Clin Invest. 2011 Nov;121(11):4393-408 [PMID: 21985788]
Nat Commun. 2019 Jun 27;10(1):2824 [PMID: 31249305]
Front Immunol. 2021 Sep 17;12:709759 [PMID: 34603283]
Hepatology. 2004 Mar;39(3):635-44 [PMID: 14999682]
Cardiovasc Res. 2002 Jul;55(1):38-52 [PMID: 12062707]
Immunity. 2003 Aug;19(2):159-63 [PMID: 12932349]
Nature. 2020 Jan;577(7790):405-409 [PMID: 31775156]
Cell Cycle. 2012 Feb 1;11(3):439-45 [PMID: 22262173]
J Clin Invest. 1996 Oct 15;98(8):1737-44 [PMID: 8878423]
Mol Cell Biol. 1989 Jul;9(7):2847-53 [PMID: 2779549]
Science. 2020 Sep 4;369(6508):1210-1220 [PMID: 32788292]
Biochem J. 2003 Aug 15;374(Pt 1):1-20 [PMID: 12773095]
Circulation. 2003 Aug 12;108(6):748-53 [PMID: 12860906]
J Biol Chem. 1996 Dec 20;271(51):32635-43 [PMID: 8999038]
Proc Natl Acad Sci U S A. 1986 Dec;83(24):9739-43 [PMID: 3540948]
J Mol Cell Cardiol. 2002 Dec;34(12):1681-91 [PMID: 12505065]
Eur J Cell Biol. 2012 Jun-Jul;91(6-7):552-66 [PMID: 21982586]
J Mol Cell Cardiol. 1997 Aug;29(8):2027-39 [PMID: 9281436]
FASEB J. 2009 Mar;23(3):774-82 [PMID: 19019853]
Cardiovasc Res. 2011 Aug 1;91(3):402-11 [PMID: 21345805]
PLoS One. 2012;7(8):e43155 [PMID: 22937020]
Mol Cell Biochem. 2000 Oct;213(1-2):17-28 [PMID: 11129954]
Circulation. 1996 Nov 15;94(10):2626-32 [PMID: 8921810]
J Neurochem. 2000 Aug;75(2):563-75 [PMID: 10899931]
Int J Exp Pathol. 2000 Feb;81(1):1-16 [PMID: 10718860]
FEBS Lett. 1999 Oct 15;459(3):453-7 [PMID: 10526183]
Circulation. 2018 Jan 2;137(1):57-70 [PMID: 29030345]
ISRN Inflamm. 2013 Dec 08;2013:512103 [PMID: 24381786]
Nat Med. 2015 Apr;21(4):353-62 [PMID: 25751817]
Am J Pathol. 1998 Jan;152(1):101-11 [PMID: 9422528]
Cardiovasc Res. 2020 Jul 1;116(8):1410-1423 [PMID: 32154891]
Cytokine Growth Factor Rev. 2015 Oct;26(5):545-58 [PMID: 26198770]
Biochem J. 1994 Jun 1;300 ( Pt 2):281-90 [PMID: 8002928]
Int J Mol Sci. 2022 Jan 17;23(2): [PMID: 35055176]
J Biol Chem. 1994 Feb 25;269(8):6215-22 [PMID: 8119965]
Cardiovasc Res. 2010 Oct 1;88(1):7-15 [PMID: 20562423]

Grants

  1. Antragsnummer 18 - 018 and 20 - 006/Willy Robert Pitzer Stiftung
  2. 973038 MAPK/William G. Kerckhoff Herz- und Rheumazentrum Bad Nauheim

MeSH Term

Animals
Cytokine Receptor gp130
Heart Failure
Humans
Interleukin-6
Mice
Myocytes, Cardiac
Oncostatin M
Oncostatin M Receptor beta Subunit
Receptors, Oncostatin M

Chemicals

Interleukin-6
OSM protein, human
OSMR protein, human
Oncostatin M Receptor beta Subunit
Receptors, Oncostatin M
Oncostatin M
Cytokine Receptor gp130
Journal Article Review

Word Cloud

Similar Articles

Cited By